DES (Diethylstilbestrol) Info

Call Website Contact the business

DES (Diethylstilbestrol) Info We welcome everyone from the DES community -- Mothers, Daughters, Sons, 3rd Generation and all exposed! In some clinics, it was given to every pregnant patient.

DES Info Association:

The DES tragedy of in-utero exposure and its devastating effects on multiple generations must not be forgotten. The medical community need education about the sequela of DES Exposure. (1) know how to screen the DES exposed, (2) Know the continueing long term effects of DES exposure, and (3) Provide prompt care when DES Exposed patients develop complications.

** What is DES (diethylstilbestrol)? **

DES (diethylstilbestrol), is a teratogenic and carcinogenic synthetic estrogen (Endocrine Disruptor) , is the world’s first major drug disaster. It was prescribed to millions of pregnant women for decades: from 1938 into the 1970s in the United States; and until the mid-1980s in parts of Latin America, Europe, Australia, and the Third World (Currently in Kenya). The currently proven effects of exposure include a rare vaginal cancer in DES Daughters; greater risk for breast cancer in DES Mothers; possible risk for testicular cancer in DES Sons, along with transgender and reproductive malformations; abnormal reproductive organs; infertility; high-risk pregnancies; Skeletal issues and an increased risk for breast cancer in DES Daughters. There are a number of other suspected effects, including auto-immune disorders, but many of these effects are still awaiting further research. For decades, Big Pharma claimed DES prevented miscarriages and problem pregnancies. It was sometimes given as an injection, but primarily it was prescribed in pill form. Never patented, DES was marketed under 200 different names, although the majority of the drug was actually produced by Eli Lilly. DES was sometimes even included in prescription prenatal vitamins. As early as 1938, studies showed that DES promoted cancer in lab animals. But at that time, people thought animal studies only provided a hint of what could happen in humans. Also, no one knew that drugs could cross the placenta and affect a baby in utero. (Note there was a 1941 mouse study that showed mice with absent or deformed fallopian tubes. The warning signs were there for humans.) In 1941, the original clinical uses for DES were to treat gonorrheal vaginitis, senile vaginitis, menopausal symptoms and to suppress lactation. Between 1941 and 1947, it was used for pregnancy without FDA approval. No controlled studies were ever conducted by the drug companies to determine the effectiveness or safety of DES for use during pregnancy, even after some scientists started questioning its efficacy in the 1950s. As early as 1953, research revealed that DES did not work (The Dieckmann Study) – that DES actually brought about higher rates of premature birth and infant mortality – yet DES continued to be prescribed to pregnant women for decades. This is because pharmaceutical companies continued to heavily promote DES use to doctors. The drug was a top moneymaker for Big Pharma. In the late 1960s, there was an unprecedented appearance of rare cancer in young women. Clear cell cancer (CCA) – a rare cancer of the vagina – was diagnosed in an age group never before found to develop it. (Normally elderly women developed CCA.) There were eight such cases at Massachusetts General Hospital in Boston alone. One of the mothers raised the question of whether her daughter's cancer might be connected to DES exposure in utero. Doctors discovered the DES link in 1971 and published their findings in the April 1971 issue of New England Journal of Medicine. News of the cancer cases made national headlines. However, the FDA did not act on this information until public pressure, including Congressional Hearings, forced the FDA to issue a warning about DES in November 1971. The drug was not banned for human use. DES was contraindicated for pregnancy by the FDA in 1972. It was not until September 2000 that the FDA finally withdrew its approval of DES for humans. Researchers are now investigating whether DES health issues are extending into the next generation, the so-called DES Grandchildren (Third Generation). As study results come in, there is growing evidence that this group has been adversely impacted by a drug prescribed to their grandmothers. To this day, not one drug company has ever apologized or accepted responsibility for the DES tragedy. Nevertheless, they have paid millions in out-of-court settlements and verdicts to DES Daughters and Sons who suffered injuries from their exposure. Please join us in our mission to continue to provide information to the DES exposed on DES information and other health related information along with pushing for more physician education to know how to care for the DES exposed. Also, we are continuing to push for more research! Our moto is "Knowledge is Power" DES Info Association is a free resource for Diethylstilbestrol Information and Research

“DISCLAIMER: THIS SITE DOES NOT PROVIDE MEDICAL ADVICE. The information on this site, including but not limited to text, graphics, images and other material, is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. If you have any questions about how the information contained on this website may relate to you, you should seek the advice of a physician or other qualified health care professional.”

DES Info: DES-associated va**nal clear cell adenocarcinoma returns in a new location 15 years later.Hall WB, Detterbeck ...
10/29/2026

DES Info: DES-associated va**nal clear cell adenocarcinoma returns in a new location 15 years later.

Hall WB, Detterbeck FC, Livasy CA, Fowler WC Jr. “Endobronchial clear cell adenocarcinoma occurring in a patient 15 years after treatment for DES-associated va**nal clear cell adenocarcinoma.” Gynecol Oncol. 2004 Jun;93(3):708-10. doi: 10.1016/j.ygyno.2004.03.014. PMID: 15196869.

A sad report: “This is a case report of a solitary endobronchial clear cell adenocarcinoma occurring 15.3 years after the initial diagnosis of DES-induced CCA.”

“This case suggests that management of clear cell cancer survivors should involve long-term follow-up because of the potential for the appearance of a new focus of clear cell adenocarcinoma.”

https://pubmed.ncbi.nlm.nih.gov/15196869/

The DES Tragedy…. The importance of follow up care!


[email protected]

This case suggests that management of clear cell cancer survivors should involve long-term follow-up because of the potential for the appearance of a new focus of clear cell adenocarcinoma.

DES Info: A DES Daughter shares her DES Journey.I was told at 12 that I was a DES daughter and that I would probably get...
10/28/2026

DES Info: A DES Daughter shares her DES Journey.

I was told at 12 that I was a DES daughter and that I would probably get cancer. My mother never had any indication of a miscarriage, but she was 32 years old, having her first pregnancy and was given DES from the start, "just in case!"

I started Pap smears, every 6 months, at age 12. I developed the cervical cancer in my twenties. That's when my mother's doctor destroyed her medical records. I had to have two cryosurgeries to remove it.

I had 4 miscarriages. I was also diagnosed with endometriosis and subsequently 6 abdominal surgeries for this and had to take anti-estrogen drugs.

In my 40s, I developed stage 3 breast cancer. I had just had a mammogram less than 5 months prior to me finding the lump. I underwent a bilateral mastectomy along with chemo and radiation, then a hysterectomy. I've been on Arimidex for 9 years.

The chemo drugs have made me allergic to the sun and I've now had skin cancer. The dermatologist also told me that DES children are higher risk for skin cancer too.

What is really perverse to me is that drug companies made millions from our mothers selling them this drug, now they are making billions on cancer treatments for us.

DES Info: Thank you for sharing your DES story. The many voices of DES need to be heard..



[email protected]

DES Info: Myeloid leukemia in an infant – Grandmother took DES!Chantrain, C.F., Sauvage, D., Brichard, B., Dupont, S., P...
10/27/2026

DES Info: Myeloid leukemia in an infant – Grandmother took DES!

Chantrain, C.F., Sauvage, D., Brichard, B., Dupont, S., Poirel, H.A., Ameye, G., De Weer, A., Vandenberghe, P., Detaille, T., Anslot, C., de Cléty, S.C. and Vermylen, C. (2009), Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero. Pediatr. Blood Cancer, 53: 220-222. https://doi.org/10.1002/pbc.22040

This report concludes with the following: “This case shows acute myeloid leukemia and the third pediatric leukemia reported after maternal diethylstilboestrol exposure.”

https://pubmed.ncbi.nlm.nih.gov/19405140/

For further information, please review the article or contact DES Info Association: [email protected]. Please include the title of the article.



[email protected]

DES Info: Insights into DES-sons’ abnormalities ..Jenny A. Visser, Anke McLuskey, Miriam Verhoef-Post, Piet Kramer, J. A...
10/21/2026

DES Info: Insights into DES-sons’ abnormalities ..

Jenny A. Visser, Anke McLuskey, Miriam Verhoef-Post, Piet Kramer, J. Anton Grootegoed, Axel P. N. Themmen, “Effect of Prenatal Exposure to Diethylstilbestrol on Müllerian Duct Development in Fetal Male Mice”

*This work was supported by The Netherlands Organization for Scientific Research (NWO) through GB-MW (Medical Sciences).
Endocrinology, Volume 139, Issue 10, 1 October 1998, Pages 4244–4251,

https://doi.org/10.1210/endo.139.10.6215
https://pubmed.ncbi.nlm.nih.gov/9751506/

This study concludes with the following:
“Therefore, it is concluded that prenatal DES exposure of male mice delays the onset of Mullerian duct development, which may result in an asynchrony in the timing of Mullerian duct formation, with respect to the critical period of Mullerian duct regression, leading to persistence of Mullerian duct remnants in male mice.”
For further information, please review the article or contact DES Info Association: [email protected]. Please include the title of the article.



[email protected]

The clinical use of diethylstilbestrol (DES) by pregnant women has resulted in an increased incidence of ge***al carcinoma in the daughters born from these pregnancies. Also, in the so-called DES-sons abnormalities were found, mainly, the presence of Müllerian duct remnants, which indicates that fe...

DES  Info: Just in... will ask for DES to be addressed
10/19/2026

DES Info: Just in... will ask for DES to be addressed

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1. Purpose and Every child deserves a safe and nurturing home where they can learn, grow, and reach their full potential. Adoption makes that possible by opening...

10/19/2026

DES Info: DES Daughter’s and Breast Screening Guidelines.

Camp EA, Coker AL, Robboy SJ, Noller KL, Goodman KJ, Titus-Ernstoff LT, Hatch EE, Herbst AL, Troisi R, Kaufman RH, Adam E. “Breast cancer screening in women exposed in utero to diethylstilbestrol.” J Womens Health (Larchmt). 2009 Apr;18(4):547-52. doi: 10.1089/jwh.2007.0580. PMID: 19361323; PMCID: PMC2857514.

Researchers examined these questions.

Their findings included the following:
• “The majority of DES-exposed women receive breast cancer screenings at least at recommended intervals, but over two-thirds do not perform monthly BSEs (breast self-exams).”
• “There is a need for greater awareness among health care providers about the higher risk of breast cancer for DES Daughters.”
• “This DES-exposed population of women will require future efforts to notify them of their increased risk and remind them of the importance of preventative examinations.”
• “It’s vital that DES Daughters — and all women — check their breasts monthly and report changes immediately. It’s another way that we can be proactive in our own health care.”

https://journals.sagepub.com/doi/10.1089/jwh.2007.0580

DES Info: We believe that physicians have a responsibility for any patient with DES exposure history. All health care providers consulted by DES Daughters — primary care, ob/gyns, breast specialists, oncologists — should make efforts, now and in the future, to notify consumers about annual breast and pelvic screenings. Annually is still the recommended frequency for exams.

For further information, please review the article online or contact DES Info Association at [email protected]. Please include the title of the article.



[email protected]

DES Info: DES & HOXA10 geneBromer, J. G., Wu, J., Zhou, Y., & Taylor, H. S. (2009). “Hypermethylation of HOXA10 by in ut...
10/03/2026

DES Info: DES & HOXA10 gene

Bromer, J. G., Wu, J., Zhou, Y., & Taylor, H. S. (2009). “Hypermethylation of HOXA10 by in utero diethylstilbestrol exposure: An epigenetic mechanism for altered developmental programming.” The Journal of Clinical Endocrinology & Metabolism, 94(5), 1836-1836.

In this study the researchers focused on the HOXA gene: “Taylor focused on the HOXA10 genes from DES Daughter mice because they act as important regulators of tissue identity. Alterations in HOX gene expression does cause abnormalities in tissues that depend on those genes for proper development.

According to Taylor, altered gene expression, or methylation, has been associated with reproductive tract abnormalities, such as those seen in DES Daughters and Sons, along with human cancers in adulthood. This research examined how HOXA10 gene expression is altered by in utero DES exposure.”

On note is their conclusion: The DES-caused hypermethylation of the HOXA10 gene in utero does not cease after birth. Taylor found that prenatal DES exposure “results in lasting changes in gene expression, persisting well after exposure, into adulthood.”

https://pubmed.ncbi.nlm.nih.gov/19299448/



[email protected]

Diethylstilbestrol (DES) is a nonsteroidal estrogen that induces developmental anomalies of the female reproductive tract. The homeobox gene HOXA10 controls uterine organogenesis, and its expression is altered after in utero DES exposure. We hypothesized that an epigenetic mechanism underlies DES-me...

Thanks for being a top engager and making it on to my weekly engagement list! 🎉 David Barraza, Leslie Merrill, Rosabella...
09/28/2026

Thanks for being a top engager and making it on to my weekly engagement list! 🎉 David Barraza, Leslie Merrill, Rosabellas Hollow, Jude Denzer, Ian Cameron-Fleming

DES Info: DES ~ Cardiovascular Disease Risk!Troisi, Rebecca, et al. "A prospective cohort study of prenatal diethylstilb...
09/21/2026

DES Info: DES ~ Cardiovascular Disease Risk!

Troisi, Rebecca, et al. "A prospective cohort study of prenatal diethylstilbestrol exposure and cardiovascular disease risk." The Journal of Clinical Endocrinology & Metabolism 103.1 (2018): 206-212.

This is an important finding and recommend you alert your physicians!

“Preliminary evidence from the National Cancer Institute (NCI) Combined DES Cohort Follow-up Study suggested a possible excess of CVD in women who were prenatally exposed to DES, but this was based on participants’ CVD report without verification.”
“In this paper, we update findings with additional follow-up and include physician-verified CVD diagnoses in a study of documented human exposure to DES in utero.”

https://pubmed.ncbi.nlm.nih.gov/29069384/

For further information, please review the article online or contact DES Info Association at [email protected]. Please include the title of the article.



[email protected]

These data demonstrate associations in women who have prenatal DES exposure with CAD and MI, but not with stroke, which appear to be independent of established CVD risk factors.

Address

Dallas, TX

Alerts

Be the first to know and let us send you an email when DES (Diethylstilbestrol) Info posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to DES (Diethylstilbestrol) Info:

Shortcuts

Share